Session

IBD (Posters)

ENDOSCOPIC MAYO SUBSCORE FAILS IN ULCERATIVE COLITIS WITH CONCOMITANT PRESENCE OF PRIMARY SCLEROSING CHOLANGITIS
ENDOSCOPIC MAYO SUBSCORE FAILS IN ULCERATIVE COLITIS WITH CONCOMITANT PRESENCE OF PRIMARY SCLEROSING CHOLANGITIS

IBD (Posters)  et al.

INFLAMMATORY BOWEL DISEASE PATIENTS REQUIRING SURGERY CAN BE TREATED IN REFERRAL CENTRES REGARDLESS OF THE COVID-19 STATUS OF THE HOSPITAL: RESULTS OF A MULTICENTRIC EUROPEAN STUDY DURING THE FIRST COVID-19 OUTBREAK (COVIBD-SURG)
INFLAMMATORY BOWEL DISEASE PATIENTS REQUIRING SURGERY CAN BE TREATED IN REFERRAL CENTRES REGARDLESS OF THE COVID-19 STATUS OF THE HOSPITAL: RESULTS OF A MULTICENTRIC EUROPEAN STUDY DURING THE FIRST COVID-19 OUTBREAK (COVIBD-SURG)

IBD (Posters)  et al.

FAECALIBACTERIUM PRAUSNITZII MODULATES INTESTINAL MUCOSAL HEALTH VIA HIF1ALPHA-INDUCED EPITHELIAL PRODUCTION OF IL-18
FAECALIBACTERIUM PRAUSNITZII MODULATES INTESTINAL MUCOSAL HEALTH VIA HIF1ALPHA-INDUCED EPITHELIAL PRODUCTION OF IL-18

IBD (Posters)  et al.

HIGH DISEASE BURDEN OF CROHN'S DISEASE (CD) IN A LATIN AMERICAN IBD REFERENCE CENTER
HIGH DISEASE BURDEN OF CROHN'S DISEASE (CD) IN A LATIN AMERICAN IBD REFERENCE CENTER

IBD (Posters)  et al.

PATIENT PREFERENCES REGARDING TREATMENT WITH ADVANCED THERAPIES IN ULCERATIVE COLITIS: A DISCRETE-CHOICE EXPERIMENT
PATIENT PREFERENCES REGARDING TREATMENT WITH ADVANCED THERAPIES IN ULCERATIVE COLITIS: A DISCRETE-CHOICE EXPERIMENT

IBD (Posters)  et al.

MICRONUTRIENT DEFICIENCY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - NEGLECTED ENTITY?
MICRONUTRIENT DEFICIENCY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - NEGLECTED ENTITY?

IBD (Posters)  et al.

LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN IBD
LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN IBD

IBD (Posters)  et al.

PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF ADALIMUMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING ADALIMUMAB BIOSIMILAR SB5; BASELINE RESULTS
PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF ADALIMUMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING ADALIMUMAB BIOSIMILAR SB5; BASELINE RESULTS

IBD (Posters)  et al.

FACTORS INDEPENDENTLY ASSOCIATED WITH FATIGUE IN IBD: RESULTS FROM THE BASELINE DATASET OF THE PREDICCT STUDY
FACTORS INDEPENDENTLY ASSOCIATED WITH FATIGUE IN IBD: RESULTS FROM THE BASELINE DATASET OF THE PREDICCT STUDY

IBD (Posters)  et al.

STRUCTURAL ALTERATIONS OF COLONIC MICROVILLI IN MICROSCOPIC COLITIS AND RESTORATION BY ORAL BUDESONIDE
STRUCTURAL ALTERATIONS OF COLONIC MICROVILLI IN MICROSCOPIC COLITIS AND RESTORATION BY ORAL BUDESONIDE

IBD (Posters)  et al.

A MATCHING-ADJUSTED INDIRECT COMPARISON OF MAINTENANCE ORAL FILGOTINIB VERSUS INTRAVENOUS VEDOLIZUMAB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
A MATCHING-ADJUSTED INDIRECT COMPARISON OF MAINTENANCE ORAL FILGOTINIB VERSUS INTRAVENOUS VEDOLIZUMAB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

IBD (Posters)  et al.

THE IBD DISK IS WELL CORRELATED WITH MUCOSAL DISEASE ACTIVITY AND MAYO SCORE IN PATIENTS WITH ULCERATIVE COLITIS
THE IBD DISK IS WELL CORRELATED WITH MUCOSAL DISEASE ACTIVITY AND MAYO SCORE IN PATIENTS WITH ULCERATIVE COLITIS

IBD (Posters)  et al.

THE APA I POLYMORPHISM IN THE VITAMIN D RECEPTOR GENE IS ASSOCIATED WITH A STRICTURING BEHAVIOUR IN CROHN´S DISEASE PATIENTS
THE APA I POLYMORPHISM IN THE VITAMIN D RECEPTOR GENE IS ASSOCIATED WITH A STRICTURING BEHAVIOUR IN CROHN´S DISEASE PATIENTS

IBD (Posters)  et al.

SIMPLIFIED RULES TO IDENTIFY BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE WITH HIGHER LIKELIHOOD OF CLINICAL REMISSION WHEN INITIATING VEDOLIZUMAB VERSUS ANTI-TNF THERAPIES: ANALYSIS OF EVOLVE STUDY DATA
SIMPLIFIED RULES TO IDENTIFY BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE WITH HIGHER LIKELIHOOD OF CLINICAL REMISSION WHEN INITIATING VEDOLIZUMAB VERSUS ANTI-TNF THERAPIES: ANALYSIS OF EVOLVE STUDY DATA

IBD (Posters)  et al.

MY IBD CARE, A DIGITAL THERAPEUTIC FOR IBD, IS SAFE AND EFFECTIVE: CASE-CONTROL STUDY IN TWO UK CENTRES
MY IBD CARE, A DIGITAL THERAPEUTIC FOR IBD, IS SAFE AND EFFECTIVE: CASE-CONTROL STUDY IN TWO UK CENTRES

IBD (Posters)  et al.

SERUM PREVALENCE OF SARS-COV2 ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE BEFORE VACCINATION
SERUM PREVALENCE OF SARS-COV2 ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE BEFORE VACCINATION

IBD (Posters)  et al.

THE NATURAL HISTORY OF COVID-19 IN PATIENTS WITH IBD: A NATIONWIDE STUDY BY THE HELLENIC SOCIETY FOR THE STUDY OF IBD
THE NATURAL HISTORY OF COVID-19 IN PATIENTS WITH IBD: A NATIONWIDE STUDY BY THE HELLENIC SOCIETY FOR THE STUDY OF IBD

IBD (Posters)  et al.

INTESTINAL FIBROBLASTS FROM CROHN’S DISEASE PATIENTS EXPRESSED INCREASED AUTOPHAGY AND DECREASED APOPTOSIS
INTESTINAL FIBROBLASTS FROM CROHN’S DISEASE PATIENTS EXPRESSED INCREASED AUTOPHAGY AND DECREASED APOPTOSIS

IBD (Posters)  et al.

FAECAL MICROBIAL TRANSPLANTATION VERSUS 5-ASA ENEMA FOR TREATMENT OF ACTIVE LEFT-SIDED ULCERATIVE COLITIS – RESULTS FROM RANDOMIZED CONTROL TRIAL FACTU
FAECAL MICROBIAL TRANSPLANTATION VERSUS 5-ASA ENEMA FOR TREATMENT OF ACTIVE LEFT-SIDED ULCERATIVE COLITIS – RESULTS FROM RANDOMIZED CONTROL TRIAL FACTU

IBD (Posters)  et al.

IMMUNOLOGICAL MECHANISMS BEHIND RESISTANCE TO BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE MOLECULAR RESISTANCE TO BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE
IMMUNOLOGICAL MECHANISMS BEHIND RESISTANCE TO BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE MOLECULAR RESISTANCE TO BIOLOGICAL THERAPY IN INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

Item 501 - 520 / 567
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
26
27 28 29